Abstract：
Breast and ovarian cancer account for over 30% of malignant pleural effusions (MPEs). Treatment of the metastatic disease requires control of the MPE. Even though primarily symptomatic, the treatment of the MPE can potentially affect the oncological course of the disease. The aim of this review is to analyze the effectiveness of intrathoracic chemotherapy in the treatment of MPE caused by breast and ovarian cancer.
A systematic literature research was conducted up until May 2021. Studies published in English on patients undergoing either surgical or interventional intrapleural chemotherapy were included.
Thirteen studies with a total of 497 patients were included. Analysis was performed on 169 patients with MPE due to breast cancer and eight patients with MPE secondary to ovarian cancer. The pooled success rates of intrathoracic chemotherapy for controlling the MPE were 59.1% and 87.5%, respectively. A survival analysis was not possible with the available data. The overall toxicity of the treatment was low.
Intrathoracic chemotherapy achieves symptomatic control of the MPE in 59.1% of patients with metastatic breast cancer and 87.5% of patients with metastatic ovarian cancer. This is inferior to other forms of surgical pleurodesis. Data from small case series and studies on intraperitoneal chemotherapy show promising results. However, formal oncological studies on the use of intrathoracic chemotherapy for metastatic breast or ovarian cancer are lacking. Further prospective pilot studies are needed to assess the therapeutic oncological effects of this treatment.
A systematic literature research was conducted up until May 2021. Studies published in English on patients undergoing either surgical or interventional intrapleural chemotherapy were included.
Thirteen studies with a total of 497 patients were included. Analysis was performed on 169 patients with MPE due to breast cancer and eight patients with MPE secondary to ovarian cancer. The pooled success rates of intrathoracic chemotherapy for controlling the MPE were 59.1% and 87.5%, respectively. A survival analysis was not possible with the available data. The overall toxicity of the treatment was low.
Intrathoracic chemotherapy achieves symptomatic control of the MPE in 59.1% of patients with metastatic breast cancer and 87.5% of patients with metastatic ovarian cancer. This is inferior to other forms of surgical pleurodesis. Data from small case series and studies on intraperitoneal chemotherapy show promising results. However, formal oncological studies on the use of intrathoracic chemotherapy for metastatic breast or ovarian cancer are lacking. Further prospective pilot studies are needed to assess the therapeutic oncological effects of this treatment.
摘要：
乳腺癌和卵巢癌占恶性胸腔积液（MPE）的30％以上。转移性疾病的治疗需要控制MPE。即使主要是症状，MPE的治疗可能会影响疾病的肿瘤病程。本综述旨在分析胸腔内化疗治疗乳腺癌和卵巢癌所致MPE的有效性。
系统的文献研究一直进行到2021年5月。包括以英文发表的有关接受手术或介入性胸膜内化疗的患者的研究。
共纳入13项研究，共497名患者。对169例乳腺癌MPE患者和8例卵巢癌MPE患者进行了分析。胸腔内化疗控制MPE的总成功率分别为59.1%和87.5%，分别。使用可用数据进行生存分析是不可能的。治疗的总体毒性低。
在59.1%的转移性乳腺癌患者和87.5%的转移性卵巢癌患者中，胸腔内化疗实现了MPE的症状控制。这是不如其他形式的手术胸膜固定术。来自小病例系列和腹膜内化疗研究的数据显示了有希望的结果。然而,目前尚缺乏对转移性乳腺癌或卵巢癌使用胸腔内化疗的正式肿瘤学研究.需要进一步的前瞻性试点研究来评估这种治疗的治疗肿瘤效果。
系统的文献研究一直进行到2021年5月。包括以英文发表的有关接受手术或介入性胸膜内化疗的患者的研究。
共纳入13项研究，共497名患者。对169例乳腺癌MPE患者和8例卵巢癌MPE患者进行了分析。胸腔内化疗控制MPE的总成功率分别为59.1%和87.5%，分别。使用可用数据进行生存分析是不可能的。治疗的总体毒性低。
在59.1%的转移性乳腺癌患者和87.5%的转移性卵巢癌患者中，胸腔内化疗实现了MPE的症状控制。这是不如其他形式的手术胸膜固定术。来自小病例系列和腹膜内化疗研究的数据显示了有希望的结果。然而,目前尚缺乏对转移性乳腺癌或卵巢癌使用胸腔内化疗的正式肿瘤学研究.需要进一步的前瞻性试点研究来评估这种治疗的治疗肿瘤效果。
